Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review

Elias Jabbour, Jorge Cortes, Hagop Kantarjian

Research output: Contribution to journalReview article

Abstract

Introduction: Chronic myelogenous leukemia (CML) is a progressive and often fatal hematopoietic neoplasm. The Bcr-Abl tyrosine kinase inhibitor imatinib mesylate represented a major therapeutic advance over conventional CML therapy, with more than 90% of patients obtaining complete hematologic response, and 70%-80% of patients achieving a complete cytogenetic response. Despite the high efficacy of imatinib, a minority of patients in chronic phase CML and more patients in advanced phases are resistant to imatinib, or develop resistance during treatment. This is attributed, in 40% to 50% of cases, to the development of mutations in the Bcr-Abl tyrosine kinase domain that impair imatinib binding. Attempts to circumvent resistance led to the discovery of nilotinib (Tasigna), a novel, potent and selective oral Bcr-Abl kinase inhibitor. Aims: To review the evidence for the use of nilotinib in the management of CML. Evidence review: Preclinical and clinical investigations demonstrate that nilotinib effectively overcomes imatinib resistance, and has further improved the treatment of CML. Place in therapy: Nilotinib is currently indicated for patients with CML in chronic and accelerated phases following imatinib failure. Randomized studies are ongoing to assess the efficacy of nilotinib in patients with newly diagnosed CML.

Original languageEnglish (US)
Pages (from-to)207-213
Number of pages7
JournalCore Evidence
Volume4
StatePublished - Dec 1 2009
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
bcr-abl Fusion Proteins
Therapeutics
Leukemia, Myeloid, Chronic Phase
Hematologic Neoplasms
Cytogenetics
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide
Imatinib Mesylate
Phosphotransferases
Mutation

Keywords

  • CML
  • Imatinib-resistance
  • Imatinibintolerance
  • Nilotinib
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Reviews and References, Medical
  • Pharmacology

Cite this

Nilotinib for the treatment of chronic myeloid leukemia : An evidence-based review. / Jabbour, Elias; Cortes, Jorge; Kantarjian, Hagop.

In: Core Evidence, Vol. 4, 01.12.2009, p. 207-213.

Research output: Contribution to journalReview article

@article{09cace66c7284379992906695c802438,
title = "Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review",
abstract = "Introduction: Chronic myelogenous leukemia (CML) is a progressive and often fatal hematopoietic neoplasm. The Bcr-Abl tyrosine kinase inhibitor imatinib mesylate represented a major therapeutic advance over conventional CML therapy, with more than 90{\%} of patients obtaining complete hematologic response, and 70{\%}-80{\%} of patients achieving a complete cytogenetic response. Despite the high efficacy of imatinib, a minority of patients in chronic phase CML and more patients in advanced phases are resistant to imatinib, or develop resistance during treatment. This is attributed, in 40{\%} to 50{\%} of cases, to the development of mutations in the Bcr-Abl tyrosine kinase domain that impair imatinib binding. Attempts to circumvent resistance led to the discovery of nilotinib (Tasigna), a novel, potent and selective oral Bcr-Abl kinase inhibitor. Aims: To review the evidence for the use of nilotinib in the management of CML. Evidence review: Preclinical and clinical investigations demonstrate that nilotinib effectively overcomes imatinib resistance, and has further improved the treatment of CML. Place in therapy: Nilotinib is currently indicated for patients with CML in chronic and accelerated phases following imatinib failure. Randomized studies are ongoing to assess the efficacy of nilotinib in patients with newly diagnosed CML.",
keywords = "CML, Imatinib-resistance, Imatinibintolerance, Nilotinib, Tyrosine kinase inhibitors",
author = "Elias Jabbour and Jorge Cortes and Hagop Kantarjian",
year = "2009",
month = "12",
day = "1",
language = "English (US)",
volume = "4",
pages = "207--213",
journal = "Core Evidence",
issn = "1555-1741",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Nilotinib for the treatment of chronic myeloid leukemia

T2 - An evidence-based review

AU - Jabbour, Elias

AU - Cortes, Jorge

AU - Kantarjian, Hagop

PY - 2009/12/1

Y1 - 2009/12/1

N2 - Introduction: Chronic myelogenous leukemia (CML) is a progressive and often fatal hematopoietic neoplasm. The Bcr-Abl tyrosine kinase inhibitor imatinib mesylate represented a major therapeutic advance over conventional CML therapy, with more than 90% of patients obtaining complete hematologic response, and 70%-80% of patients achieving a complete cytogenetic response. Despite the high efficacy of imatinib, a minority of patients in chronic phase CML and more patients in advanced phases are resistant to imatinib, or develop resistance during treatment. This is attributed, in 40% to 50% of cases, to the development of mutations in the Bcr-Abl tyrosine kinase domain that impair imatinib binding. Attempts to circumvent resistance led to the discovery of nilotinib (Tasigna), a novel, potent and selective oral Bcr-Abl kinase inhibitor. Aims: To review the evidence for the use of nilotinib in the management of CML. Evidence review: Preclinical and clinical investigations demonstrate that nilotinib effectively overcomes imatinib resistance, and has further improved the treatment of CML. Place in therapy: Nilotinib is currently indicated for patients with CML in chronic and accelerated phases following imatinib failure. Randomized studies are ongoing to assess the efficacy of nilotinib in patients with newly diagnosed CML.

AB - Introduction: Chronic myelogenous leukemia (CML) is a progressive and often fatal hematopoietic neoplasm. The Bcr-Abl tyrosine kinase inhibitor imatinib mesylate represented a major therapeutic advance over conventional CML therapy, with more than 90% of patients obtaining complete hematologic response, and 70%-80% of patients achieving a complete cytogenetic response. Despite the high efficacy of imatinib, a minority of patients in chronic phase CML and more patients in advanced phases are resistant to imatinib, or develop resistance during treatment. This is attributed, in 40% to 50% of cases, to the development of mutations in the Bcr-Abl tyrosine kinase domain that impair imatinib binding. Attempts to circumvent resistance led to the discovery of nilotinib (Tasigna), a novel, potent and selective oral Bcr-Abl kinase inhibitor. Aims: To review the evidence for the use of nilotinib in the management of CML. Evidence review: Preclinical and clinical investigations demonstrate that nilotinib effectively overcomes imatinib resistance, and has further improved the treatment of CML. Place in therapy: Nilotinib is currently indicated for patients with CML in chronic and accelerated phases following imatinib failure. Randomized studies are ongoing to assess the efficacy of nilotinib in patients with newly diagnosed CML.

KW - CML

KW - Imatinib-resistance

KW - Imatinibintolerance

KW - Nilotinib

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=79959371494&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959371494&partnerID=8YFLogxK

M3 - Review article

C2 - 20694077

AN - SCOPUS:79959371494

VL - 4

SP - 207

EP - 213

JO - Core Evidence

JF - Core Evidence

SN - 1555-1741

ER -